Clinical Trial Update: Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety and tolerability update for ISIS EIF4E Rx in combination with docetaxel and prednisone in castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castrate-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ISIS EIF4E Rx
• PREDNISONE (Prednisone)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Castrate-Resistant Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED